HC Wainwright Reiterates Buy Rating on Edgewise Therapeutics

HC Wainwright has reiterated its buy rating on Edgewise Therapeutics, Inc. (NasdaqGS: EWTX) with a price target of $45. This reaffirmation came on June 16, 2026, as analyst Lander Egaña Gorroño expressed continued confidence in the company's potential.

Other Institutional Activity in Edgewise Therapeutics

Several institutional investors have shown varied interest in Edgewise Therapeutics. ORBIMED Advisors LLC maintained its position with 15,518,492 shares valued at about $488.8 million. RA Capital Management, L.P. also held steady with 10,428,437 shares worth approximately $328.5 million. Paradigm Biocapital Advisors LP increased its stake by 823,828 shares, bringing its total to 7,365,038 shares valued at $232 million. Meanwhile, BlackRock, Inc. trimmed its holdings by 157,585 shares, ending with 6,472,991 shares valued at around $203.9 million. Janus Henderson Group PLC made a notable increase, adding 1,348,706 shares to hold a total of 5,915,556 shares worth about $186.3 million.

Edgewise Therapeutics Stock Snapshot

Shares of Edgewise Therapeutics (NasdaqGS: EWTX) are trading near $35.21. The company has a market cap of approximately $3.79 billion and is not yet profitable, reflected in its negative forward P/E ratio. The stock has a 52-week range between $12.15 and $40.77, with a 50-day moving average of $33.66 and a 200-day moving average of $25.68. Edgewise Therapeutics boasts a strong liquidity position with a current ratio of 22.61 and a quick ratio of 22.16.

Analysts Set New Price Targets

On June 16, 2026, HC Wainwright & Co. reiterated its buy rating on Edgewise Therapeutics with a $45 price target. Earlier in the month, on June 2, RBC Capital maintained its buy rating with a slightly higher target of $48, while Wedbush set a target of $52. Overall, the consensus recommendation remains a buy, with an average target price of $46.08 across 12 analyst opinions.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for muscle disorders. Headquartered in Boulder, Colorado, the company is led by CEO Dr. Kevin Koch. With around 154 employees, Edgewise's lead product candidate, sevasemten, is in Phase II clinical trials targeting dystrophinopathies, including Duchenne and Becker muscular dystrophy. The company is also working on treatments for hypertrophic cardiomyopathy and heart failure.

Bottom Line

HC Wainwright's reiterated buy rating and $45 price target reflect ongoing confidence in Edgewise Therapeutics' potential. The company's innovative pipeline in muscle disorder treatments continues to attract institutional interest, as seen in recent filing activity. Investors should note that analyst ratings are subject to change and reflect opinions as of the stated dates.